Killing cancer cells by flipping the Bcl-2/Bax switch.

  title={Killing cancer cells by flipping the Bcl-2/Bax switch.},
  author={Suzanne Cory and Jerry M. Adams},
  journal={Cancer cell},
  volume={8 1},
Impairment of apoptosis, the physiologic cell death process, is central to cancer development and renders tumors refractory to cytotoxic therapy. Bcl-2, the oncoprotein activated in follicular lymphoma, inhibits the conserved cell death pathway triggered by diverse cytotoxic agents, as do several close relatives. A small-molecule antagonist of these proteins has now been designed by Oltersdorf et al. Strikingly, ABT-737 sensitizes many tumors to cytotoxic agents and is effective as a single… CONTINUE READING